Five‐year survival of resectable stage IIIA non‐small cell lung cancer in Brazil

Abstract

AbstractBackgroundIn stage IIIA non‐small cell lung cancer (NSCLC), surgery plays a role in terms of multimodal treatment. Surgery rates have increased in recent years, mainly due to the combination of more accurate imaging tools, electromagnetic navigation bronchoscopy, robotic bronchoscopy, robotic surgery, and a wide range of challenging clinical scenarios to lead surgeons and oncologists to include surgery as an option in therapeutic management.ObjectivesTo assess the prognostic factors, the 5‐year overall survival (OS) and cancer‐specific survival (CSS) of patients with resectable stage III‐NSCLC.MethodsPatients' information was extracted from 76 Hospitals' Cancer Registry. OS and CSS were constructed using the Kaplan–Meier method, and the log‐rank test was used to assess differences between curves. In addition, Cox regression was conducted to evaluate the patients' characteristics leading to better OS and CSS.ResultsOverall, 433 stage III NSCLC surgical patients followed over 19 years were included. The median age was 61.29 ± 9.62 years, 58.4% male, 50.1% with adenocarcinoma, 29.3% with squamous cell carcinoma, 3.7% with large‐cell lung carcinoma, and 16,9% with other lung cancer types. The 5‐year OS was 30.6% (95% confidence interval [CI]: 27.4–36.1), and the CSS was 35.0% (95% CI: 29.4–41.0). In the Cox multivariate regression, squamous cell carcinoma was associated with reduced OS (hazard ratio [HR]: 1.40; 95% CI: 1.07–1.83; p=0.014) and CSS (HR: 1.56; 95% CI: 1.17–2.08; p = 0.002), in comparison with adenocarcinoma. The 2015–2019 quinquennial had a 50% reduction in HR (0.49; 95% CI: 0.29–0.81; p = 0.006), and the 2010–2014 group had a 40% reduction (0.59; 95% CI: 0.42–0.83; p = 0.006) in comparison with the 2000–2004 patients' group.ConclusionThe OS and CSS of patients with resectable stage III NSCLC have improved over the past 19 years in our region. Squamous cell carcinoma was associated with increased mortality risk from any cause or specific cancer.